MedTrace Logo

Kristalose as Bowel Evacuant Prior to Colonoscopy

NCT01256541 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-10-06

No results posted yet for this study

Summary

To determine whether Kristalose causes a significant increase in hydrogen and/or methane gas levels in patients requiring bowel evacuation, and also to determine the safety, efficacy, and patient preference of Kristalose as a bowel evacuant

Conditions

  • Bowel Evacuant Prior to Colonoscopy

Interventions

DRUG

Kristalose

The dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.

Sponsors & Collaborators

  • Virginia Mason Hospital/Medical Center

    collaborator OTHER

  • Cumberland Pharmaceuticals

    collaborator INDUSTRY

  • Benaroya Research Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01256541 on ClinicalTrials.gov